HYPR Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 4.49
- P/S (TTM)
- 13.58
- EV/EBITDA
- -0.72
Profitability & growth
- ROE (TTM)
- -79.0%
- Operating margin
- -144.9%
- Revenue growth YoY
- 128.0%
- Dividend yield
- —
- Beta
- 1.42
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Hyperfine Inc
Company profileHyperfine Inc. is an innovative leader in medical technology, renowned for developing the first FDA-cleared portable MRI system that revolutionizes access to imaging at the point of care. By delivering high-quality imaging directly at the bedside, Hyperfine enhances patient care and streamlines clinical decision-making, addressing the growing demand for efficient and accessible diagnostic solutions. The company's focus on cost efficiency and patient convenience uniquely positions it within the evolving healthcare landscape, making it a compelling opportunity for institutional investors…
Classification
- Sector
- Healthcare
- Industry
- Medical Devices
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 351 NEW WHITFIELD STREET, GUILFORD, CT
- Fiscal year end
- December
- Latest quarter
- Dec 31, 2025
Educational content · Not investment advice or recommendations
We're educators, not advisors. Your decisions are your own. Disclaimer
I'm your AI thinking companion for the markets — I can help you explore and learn, but I'm not a financial advisor. Everything here is educational. Disclaimer